Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB study shows benefits of Neupro in RLS treatment

UCB study shows benefits of Neupro in RLS treatment

15th June 2011

UCB has highlighted data from a new post-hoc analysis of its rotigotine treatment Neupro, assessing its benefits against restless legs syndrome (RLS).

Presented at the International Congress of Parkinson's Disease and Movement Disorders, the study has utilised novel surrogate markers to compare the effects of Neupro with placebo in a six-month double-blind study.

Results from the analysis showed that UCB's drug is able to deliver improvements in daytime functioning and symptoms among patients, as well as reductions in RLS-related pain, improved mood and fewer depressive symptoms.

Dr Ralf Kohnen of Germany's University of Erlangen-Nuremberg said: "These effects may be explained by the 24-hour coverage of symptoms, whenever they occur, with the application of transdermal rotigotine."

Neupro is currently approved in Europe for the treatment of early-stage idiopathic Parkinson's disease as well as RLS.

The drug's strong sales have been cited by UCB as being one of the key drivers of its encouraging first-quarter financial performance.ADNFCR-8000103-ID-800579359-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.